Clinical Trial Update: Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients（Rocket Trial） [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating orelabrutinib plus R-CHOP for CD5-positive diffuse large B-cell lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Large B-cell Lymphoma

Drugs mentioned

• Orelabrutinib (orelabrutinib)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Diffuse Large B Cell Lymphoma (DLBCL) | Phase 2 | Status: RECRUITING